Company / FCF Margin
Avalo Therapeutics, Inc. FCF Margin History
FY2017-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-148.7%
FY2022
5-year range
-1315.4% / -148.7%
FY2018-FY2022
Trend
+88.7%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FCF Margin returned to growth in FY2022 after 4 years of decline, reaching -148.7%.
Based on SEC 10-K filings.
-148.7% in FY2022 with a 5-year CAGR of -193.9%.
Improved from -606.1% to -148.7% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- +138.6pp
- 5-Year Change
- -193.9pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2022, fcf margin increased 88.7% year-over-year.
- Peak fcf margin was recorded in FY2017.
- Lowest fcf margin in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -148.7% | +88.7% |
| FY2021 | -1315.4% | -117.0% |
| FY2020 | -606.1% | -110.9% |
| FY2019 | -287.3% | -446.9% |
| FY2018 | -52.5% | -216.4% |
| FY2017 | 45.1% | - |
As of FY2022 · SEC Form 10-K · Last checked Jun 21, 2026